Upcoming Webinars

High Dose Vitamin C Therapy in Critically Ill Patients
False hyperglycemia associated with POC glycemic management
November 9, 2017  7 PM   GMT

Featured Speaker:
Alexander H. Flannery, PharmD, BCCCP, BCPS, Assistant Professor, Department of Pharmacy Practice and Science Director, PGY2 Critical Care Residency, University of Kentucky HealthCare and College of Pharmacy, Lexington, KY

Vitamin C (ascorbic acid) is often used in hospitals to treat critically ill patients because of its anti-inflammatory properties, which help neutralize free radicals and reduce cellular damage. Ascorbic acid is generally considered to be safe, even in high doses, with very few side effects. Recent publications describe success with ascorbic acid adjunctive therapy in treating sepsis, a leading cause of patient readmission and death in U.S. hospitals, according to the National Institutes of Health. However, ascorbic acid is a proven interference to some point-of-care (POC) glucose meters used in hospital glycemic management, causing some meters to over-report glucose by 30% or higher. This webinar will discuss the increased risk of false hyperglycemia to patients receiving ascorbic acid infusion while also being monitored for glycemic control with glucose meters, and which meter/s that can be safely used with this therapy.

  1. Learning Objectives:
    • Describe the clinical research on intravenous ascorbic acid therapy in patients with septic shock and severe burns.
    • Design an appropriate monitoring regimen for patients on intravenous ascorbic acid therapy.
    • Identify the effect of ascorbic acid on commonly used POC glucose meters.

  2. View this recording here

The importance of measuring ionised magnesium in critically ill patients
November 16, 2017  3 – 4 PM   GMT

 

Featured Speaker:
Andrei Malic, PhD
Clinical Communications Director,
Medical and Scientific Affairs
Nova Biomedical


Dysmagnesaemia is common in critically ill patients and is associated with poor clinical outcomes. Magnesium sulphate therapy is often used to correct hypomagnesaemia but if administered without monitoring patient magnesium levels can lead to hypermagnesaemia and poorer patient outcomes. Traditionally, total magnesium (tMg) measured in the laboratory is used to identify patients with dysmagnesaemia. However this delays the clinical management of critical care patients. Several studies have shown that iMg is more reliable than tMg for identifying and managing dysmagnesaemia. As iMg is now available as a point of care test which can be used in conjunction with iCa this will benefit the management of these important cations in critically ill patients.

  1. Learning Objectives:
    • Background knowledge of the pathophysiology and role of Mg in biological processes
    • Understanding of the clinical conditions and outcomes associated with dysmagnesaemia in critical care patients
    • Background to current magnesium testing approach and limitations
    • Understanding of the clinical utility and value of point of care ionised magnesium testing in the critical care patient pathway.


  2. View this recording here

 

Bioprocess Automation for PAT with BioProfile® FLEX2 plus Seg-Flow®
14 November 2017   9 am EDT (U.S.) / 3 pm CEST / 2 pm BST


Featured Speaker:
Matt McRae

Product Line Manager,
Biotechnology Products
Nova Biomedical

Nova Biomedical develops and manufactures automated chemistry and cell culture analyzers to rapidly test key nutrients, metabolites, gases, osmolality, and cell density for mammalian cell culture and fermentation media.

This webinar will discuss an online automation solution for cell culture sampling and comprehensive analysis for bench-scale bioreactor cultures. Nova’s BioProfile FLEX2, with 16 key cell culture tests and maintenance-free sensors, can now be paired with Flownamics’ Seg-Flow online auto-sampler, enabling completely automated online sampling from up to eight bioreactor cultures.

Learning Objectives:
• Learn about FLEX2’s innovative design that provides comprehensive analysis of 16 key cell culture chemistries.
• Discover how the collaboration between Flownamics and Nova Biomedical allows off-line and at-line data to seamlessly integrate into a multifunctional online PAT tool through Seg-Flow’s communication interface.
• See how FLEX2 automation through the Seg-Flow interface reduces labor, saves costs, and provides the highest quality data possible.
• Explore real-world examples of automated analysis of micro-bioreactor cell cultures.
• Review the advantages of FLEX2’s small sample volume and unique modular design.
• Gain insight into the advantages of FLEX2’s maintenance-free MicroSensor Card™ technology.

  1. View this recording here


Featured Speaker:
Fred Schneider
Director of Sales,
Flownamics, Inc.

 


On-Demand Webinars

Preventing Intrapartum Foetal Hypoxia and Acidosis with POC Lactate

 

Featured Speaker:
Clare Bailey, MSc, FIBMS Lead Biomedical Scientist for POCT Barking, Havering and Redbridge University Hospitals Having studied Marine Biology and Zoology at Bangor University in North Wales, she began training as Biomedical Scientist in Clinical Chemistry at Southend University Hospital; completing her Bsc and Msc in Biomedical Science at the University of Greenwich. She stayed here from 2004 – 2015, where she took on the role of Senior BMS in Point of Care Testing before becoming Lead Biomedical Scientist for Point of Care for Barking, Havering and Redbridge University Hospitals covering 95 clinical areas. Clare is passionate about Point of Care Testing and is a member of the QPoint
EQAS Steering Group.

Foetal lactate estimation has long been recognised as an alternative method of establishing the presence of foetal metabolic acidaemia. With recent updates to the NICE clinical guideline 190 (for intrapartum care for healthy women and babies), more obstetricians are using lactate foetal blood sampling (FBS) to determine intrapartum foetal hypoxia and acidosis. Lactate testing can be revolutionary in cases where pH FBS testing is inappropriate or the sample is inadequate or of a poor quality. Although routinely used in Sweden, France and Australia, UK obstetricians have been hesitant to adopt lactate point-of-care testing (POCT) without evidence-based practice. This webinar will cover the benefits of lactate POCT using FBS, how lactate FBS compares to pH in identifying intrapartum foetal distress, and an overview of a NHS trust study to determine the impact of lactate POCT on the detection of foetal hypoxia and acidosis during labour.

  1. Learning Objectives:
    1. Discuss the evolving practice of lactate testing with FBS.
    2. Learn how to identify hypoxia and acidosis during labour with lactate POCT.
    3. Understand how a busy NHS trust underwent a study of lactate and pH POCT and discuss its findings.
    4. Determine whether measuring fetal scalp lactate with a POC lactate meter can help identify foetal distress and the need for intervention.
    5. Assess whether your institution could benefit from lactate POCT for foetal patients.

    Who should attend?
    • POC practitioners • Biomedical scientists • Clinical chemists • Neonatologists • Obstetricians
  2. View this recording here


Innovation in Cell Culture Analysis

 

Featured Speaker:
Matt McRae
Product Line Manager, Biotechnology Products, Nova Biomedical

Featured Speaker:
Roystein Bulman
European Biotechnology Applications,
Nova Biomedical

Nova Biomedical develops and manufactures automated chemistry and cell culture analysers to rapidly test pH, PCO2, PO2, glucose, lactate, glutamine, glutamate, ammonium, sodium, potassium, calcium, osmolality, and cell density for mammalian cell culture and fermentation media.

In this webinar, Nova’s biotechnology specialists will describe our just-released BioProfile® FLEX2 analytical system. FLEX2 combines Nova’s groundbreaking MicroSensor Card™ technology with optical measurement and freezing point osmometry for a comprehensive cell culture analyser that eliminates chemistry sensor maintenance and provides a full, 16-test panel analysis in under 4.5 minutes with a sample volume of 265µL.

  1. Discover how Nova’s innovative technology can improve your bioprocess.
    1. Learn about Nova Biomedical and our automated chemistry and cell culture analysers.
    2. Review the advantages of BioProfile® FLEX2’s unique modular design.
    3. Understand how this comprehensive, high throughput analyser benefits bioreactor analysis and process optimisation.
  2. 4. Examine how reduced sample volume can improve cell line selection and early-phase screening.
    5. Gain insight into the advantages of maintenance-free MicroSensor Card™ technology.
    6. Understand the impact of culture osmolality and the benefits of accurately measured osmolality for improved process robustness.

  3. View this recording here

 

Bedside Glucose Monitoring – Is it Safe for Critically Ill Patients?

 

Featured Speaker:
Andrei Malic,
PhD Director, Medical and Scientific Affairs
Nova Biomedical

Concern continues over the accuracy of glucose meters used in critically ill patients, as deaths and serious adverse events associated with certain meters are still being reported in the U.S. FDA MAUDE database and in peer-reviewed medical journals. Substances commonly found in the whole blood of critically ill patients often interfere with glucose measurement accuracy in these meters, which, though currently used in hospitalized critically ill patients, were originally designed for self-monitoring at home.

This webinar will present a new, regulatory-compliant risk evaluation protocol in critically ill patient care settings. It will detail the methodology, data analysis, and complex and extensive clinical risk analysis undertaken in an international, multi-site study to substantiate the performance of a glucose meter in critically ill patients.

  1. Learning Objectives:
    1. Review the history of patient safety issues associated with glucose meter use in hospitals.
    2. Describe the risk that unevaluated and non-qualified glucose meters pose to critically ill patients.
    3. Examine whether a glucose meter can be equivalent to a central laboratory, definitive reference method.
    4. Demonstrate the advanced analytical and statistical risk models needed to establish glucose meter effectiveness.
    5. Determine whether improved glucose meter technology can improve patient outcomes.
    6. Establish that a glucose meter can meet the FDA’s 2016 final guidance.

    Who should attend?
    • POC coordinators • Laboratorians • Critical care nurses • PharmD • Hospitalists
  2. View this recording here

 

Understanding Managed Service Contracts and How They Can Improve Your Point-of-Care Testing Service

Featured Speaker:
Gayle Merrygold
A leasing consultant, Gayle joined Chrystal Consulting 15 years ago and is responsible for the development of the company’s NHS business. Using her product knowledge and project management experience, Gayle has been responsible for the implementation of a variety of large-valued managed service contracts ranging from £300k to £20m. As a result, she has been able to generate significant cost savings to trusts, whilst improving clinical services.

 

Chrystal Consulting’s Gayle Merrygold will present on managed service contracts. She will define what a managed service contract is, outline the procurement process, and explain how you can improve efficiency via this method. Gayle will detail the additional benefits that managed service contracts can deliver and outline the process of implementing a contract.

View this recording here

 

Can Point-of-Care Creatinine Testing Reduce Contrast-Induced Acute Kidney Injury (CI-AKI) in STEMI Patients Treated with PPCI?

Featured Speaker:
Dr. Thomas Keeble
Consultant Cardiologist – Southend Hospital / Essex Cardiothoracic Centre
Senior Clinical Fellow – Anglia Ruskin University

CI-AKI and related nephropathy occur in approximately 15-20% of patients who are treated for acute ST elevation myocardial infarction (STEMI) with primary percutaneous coronary intervention (PPCI). CI-AKI is multi-factorial including contrast load, dehydration, existing renal dysfunction and diabetes. Thomas Keeble, MD, and his team are conducting a trial in a STEMI population undergoing PPCI, part of which involves assessing whether simple, point-of-care (POC) creatinine and eGFR measurement, which determines renal status, impacts CI-AKI and nephropathy. The study gives early indication that patients found to have renal impairment prior to PPCI can receive less contrast medium during treatment, leading to decreased incidence of CI-AKI and nephropathy.

View this recording here

 

The Sepsis Epidemic: New sepsis definitions and evidence-based treatment

Featured Speaker:
Ron Daniels, BEM
NHS Consultant in Critical Care and Anaesthesia
Co-Founder and Chief Executive, UK Sepsis Trust
CEO, Global Sepsis Alliance

Sepsis is responsible for at least 44,000 deaths in the UK annually, and accounts for 30-50% of episodes of inpatient deterioration. Despite endorsement by relevant professional agencies, the internationally recognized sepsis standards of care are achieved in fewer than 20% of cases. Evidence in support of basic care elements—antibiotics and fluid challenges—suggests that they are more effective and their delivery more time-critical than interventions in acute coronary syndrome.

View this recording here